{
    "root": "312f7be6-4524-87aa-e063-6294a90af567",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glimepiride",
    "value": "20250325",
    "ingredients": [
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "GLIMEPIRIDE",
            "code": "6KY687524K"
        }
    ],
    "indications": "Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see\n \n  Clinical Studies(\n \n  14.1)].\n\n \n                  \n                     Limitations of Use\n                  \n                  Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.",
    "contraindications": "Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. ( 2.1 ) Administer with breakfast or first meal of the day. ( 2.1 ) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment). ( 2.1 )",
    "warningsAndPrecautions": "Glimepiride tablets, USP are available in the following strengths and package sizes:\n                  4 mg tablets (blue coloured, oval shaped, biconvex, uncoated tablets debossed with ‘AHI 4’ on one side and break line on the other) in\n                  NDC: 70518-2670-00\n                  NDC: 70518-2670-01\n                  NDC: 70518-2670-02\n                  NDC: 70518-2670-03\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 180 in 1 BOTTLE PLASTIC\n                  PACKAGING: 100 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 25°C (77°F); excursions permitted to 20°C to 25°C (68°F to 77°F) (see USP Controlled Room Temperature).\n                  Dispense in well-closed containers with safety closures.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Glimepiride tablet is contraindicated in patients with a history of a hypersensitivity reaction to:\n                  \n                     Glimepiride or any of the product’s ingredients [see\n  \n   Warnings and Precautions(\n  \n   5.2)].\n \n  \n                     Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. Do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives."
}